DE60111571D1 - Verwendung von anethol-dithiolethion zur vorbeugung und behandlung der sehnentoxizität - Google Patents

Verwendung von anethol-dithiolethion zur vorbeugung und behandlung der sehnentoxizität

Info

Publication number
DE60111571D1
DE60111571D1 DE60111571T DE60111571T DE60111571D1 DE 60111571 D1 DE60111571 D1 DE 60111571D1 DE 60111571 T DE60111571 T DE 60111571T DE 60111571 T DE60111571 T DE 60111571T DE 60111571 D1 DE60111571 D1 DE 60111571D1
Authority
DE
Germany
Prior art keywords
treatment
dithiolethion
anethol
prevention
toxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60111571T
Other languages
English (en)
Other versions
DE60111571T2 (de
Inventor
Marie-Odile Christen
Jean-Michel Warnet
Patrice Rat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Medical SAS
Original Assignee
Solvay Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharma SAS filed Critical Solvay Pharma SAS
Publication of DE60111571D1 publication Critical patent/DE60111571D1/de
Application granted granted Critical
Publication of DE60111571T2 publication Critical patent/DE60111571T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Lubricants (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60111571T 2000-04-25 2001-04-25 Utilisation de l'anethole-dithiolethione dans la prevention et le traitement de la tenotoxicite induite par un medicament Expired - Fee Related DE60111571T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0005247A FR2807944B1 (fr) 2000-04-25 2000-04-25 Utilisation de l'anethole-dithiolethione dans la prevention et le traitement de la tenotoxicite induite par un medicament
FR0005247 2000-04-25
PCT/FR2001/001268 WO2001080856A2 (fr) 2000-04-25 2001-04-25 Utilisation de l'anethole-dithiolethione dans la prevention et le traitement de la tenoxicite induite par un medicament

Publications (2)

Publication Number Publication Date
DE60111571D1 true DE60111571D1 (de) 2005-07-21
DE60111571T2 DE60111571T2 (de) 2006-05-11

Family

ID=8849561

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60111571T Expired - Fee Related DE60111571T2 (de) 2000-04-25 2001-04-25 Utilisation de l'anethole-dithiolethione dans la prevention et le traitement de la tenotoxicite induite par un medicament

Country Status (12)

Country Link
US (1) US20030187067A1 (de)
EP (1) EP1351680B8 (de)
JP (1) JP2003531172A (de)
AT (1) ATE297727T1 (de)
AU (1) AU2001256406A1 (de)
CA (1) CA2406998A1 (de)
DE (1) DE60111571T2 (de)
ES (1) ES2245361T3 (de)
FR (1) FR2807944B1 (de)
HU (1) HUP0301810A2 (de)
PT (1) PT1351680E (de)
WO (1) WO2001080856A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103113360B (zh) * 2013-02-19 2015-01-28 东南大学 一种阿托伐他汀衍生物、其药物组合物及制药应用
WO2018162845A1 (fr) * 2017-03-07 2018-09-13 CHILDS, Marc Prevention des risques associes à un allongement de l'intervalle qt d'origine medicamenteuse à l'aide d'un inhibiteur specifique de la production de ros d'origine mitochondriale
WO2018162846A1 (fr) * 2017-03-07 2018-09-13 Sauzieres, Jacques Prévention des effets adverses des especes reactives de l'oxygene d'origine mitochondriale à l'aide d'un inhibiteur specifique de la production de ros d'origine mitochondriale

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma

Also Published As

Publication number Publication date
FR2807944A1 (fr) 2001-10-26
EP1351680B1 (de) 2005-06-15
US20030187067A1 (en) 2003-10-02
ES2245361T3 (es) 2006-01-01
EP1351680A2 (de) 2003-10-15
HUP0301810A2 (hu) 2003-09-29
AU2001256406A1 (en) 2001-11-07
PT1351680E (pt) 2005-10-31
ATE297727T1 (de) 2005-07-15
EP1351680B8 (de) 2005-08-17
WO2001080856A2 (fr) 2001-11-01
FR2807944B1 (fr) 2003-06-13
WO2001080856A3 (fr) 2003-04-24
DE60111571T2 (de) 2006-05-11
JP2003531172A (ja) 2003-10-21
CA2406998A1 (fr) 2001-11-01

Similar Documents

Publication Publication Date Title
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
ATE342728T1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
ATE325808T1 (de) 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE69825286D1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
DE69825440D1 (de) VERWENDUNG VON TAUROLIDINE ZUR Herstellung eines Arzneimittels zur BEHANDLUNG VON LEUKÄMIEN
NO20025405D0 (no) Modulatorer for TNF-alfa-signalisering
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE69912670D1 (de) Substituierte tricyclische Verbindungen und deren Verwendung zur Behandlung von sPLA2-bedingten Erkrankungen
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE451103T1 (de) Zusammensetzung zur behandlung von atherosklerose,die candesartan und rosuvastatin enthält
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE60111571D1 (de) Verwendung von anethol-dithiolethion zur vorbeugung und behandlung der sehnentoxizität
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE69918541D1 (de) Verwendung von nmda antagonisten zur behandlung des reizkolons
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
DE69806062T2 (de) Kombinationstherapie zur behandlung von aids
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee